Proactive Investors
29 May 2026, 20:31 UTC · 19w ago
Verdict
Headline takes no side. We score BIVI +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 90% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
BioVie Inc. expects to release top-line results from its Phase 2 long COVID trial for bezisterim by September or October.
So whatClinical trial data is the primary catalyst for biotech valuations, with the potential for significant price volatility upon release.
More positive than 94% of claims this week
BioVie has achieved full enrollment of over 200 patients for its Phase 2 long COVID study, with participants from institutions such as Yale and Mayo Clinic.
Continue reading
5 related stories
More positive than 67% of claims this week
The company has received a $13 million grant to support the exploration of bezisterim in long COVID patients.
So whatNon-dilutive funding reduces cash burn and provides a signal of institutional validation for the drug's potential.
More positive than 55% of claims this week
CEO Cuong Do claims that capturing a fraction of the 3 million severely impacted long COVID patients could lead to annual sales exceeding $10 billion.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company achieved full enrollment in its Phase 2 long COVID trial and secured a $13 million grant.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
8h ago
PRNewsWire
11h ago
−16.2%
Price is moving against the score
$1.19 vs $1.42 close before publication (May 29) · not market-adjusted
BIVI chart →
